Carboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer

BACKGROUND: We assess the prognostic value of chemotherapy-induced leukopenia and sensory neuropathy in the CALYPSO trial patients treated with carboplatin–paclitaxel (CP) or carboplatin–liposomal doxorubicin (CPLD). METHODS: We performed a landmark analysis at first month after randomisation to cor...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Lee, C K, Gurney, H, Brown, C, Sorio, R, Donadello, N, Tulunay, G, Meier, W, Bacon, M, Maenpaa, J, Petru, E, Reed, N, Gebski, V, Pujade-Lauraine, E, Lord, S, Simes, R J, Friedlander, M
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2011
Matèries:
Clinical Study
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3172911/
https://ncbi.nlm.nih.gov/pubmed/21750553
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2011.256
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars